Novo Nordisk Says CEO to Step Down Amid Stock Slump. Shares Fall 5%. - Barron's
1. CEO Lars Fruergaard Jørgensen departs due to market challenges. 2. Novo Nordisk shares down approximately 50% in the last year. 3. Increased competition from Eli Lilly impacting Novo Nordisk's stock performance. 4. Stock fell 4.3% after CEO announcement; ADRs down 5.7% premarket. 5. Leadership change amidst declining market confidence in drug pipeline.